MoonLake Immunotherapeutics Accounts Payable

The latest accounts payable for MLTX is $17M as of June 2026. That compares with $15M in the prior-year period — up 14.4% year over year. Investors often review this figure alongside MoonLake Immunotherapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, MLTX's accounts payable moved from $15M to $17M — a 14.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in MoonLake Immunotherapeutics's operating scale or balance-sheet position.

A accounts payable figure of $17M for MLTX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting MLTX's accounts payable ($17M), review year-over-year change from $15M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.